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ABSTRACT
Critically ill patients who develop acute kidney injury (AKI) are more than twice as likely to die in hospital. However, it is
not clear to what extent AKI is the cause of excess mortality, or merely a correlate of illness severity. The Bradford Hill
criteria for causality (plausibility, temporality, magnitude, specificity, analogy, experiment & coherence, biological gradient
and consistency) were applied to assess the extent to which AKI may be causative in adverse short-term outcomes of
critical illness.
Plausible mechanisms exist to explain increased risk of death after AKI, both from direct pathophysiological effects of renal
dysfunction and mechanisms of organ cross-talk in multiple-organ failure. The temporal relationship between increased
mortality following AKI is consistent with its pathophysiology. AKI is associated with substantially increased mortality, an
association that persists after accounting for known confounders. A biological gradient exists between increasing severity
of AKI and increasing short-term mortality. This graded association shares similar features to the increased mortality
observed in ARDS; an analogous condition with a multifactorial aetiology. Evidence for the outcomes of AKI from
retrospective cohort studies and experimental animal models is coherent however both of these forms of evidence have
intrinsic biases and shortcomings. The relationship between AKI and risk of death is maintained across a range of patient
ages, comorbidities and underlying diagnoses.
In conclusion many features of the relationship between AKI and short-term mortality suggest causality. Prevention and
mitigation of AKI and its complications are valid targets for studies seeking to improve short-term survival in critical care.
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INTRODUCTION
In critically ill patients, AKI is common, affecting 26–67% of
patients [1, 2], and is associated with poor patient outcomes in-
cluding an approximate doubling of the risk of death in hospital
[1, 3]. AKI survivors have poorer long-term outcomes including
increased rates of death, development or progression of chronic
kidney disease (CKD) and end-stage kidney disease (ESKD) [3–5].
While long-term outcomes are of great importance, this review
principally focuses on the well-studied association between the
development of AKI and increased hospital mortality. Despite
higher mortality rates, patients with AKI on average have more
severe underlying illness, suggesting that the poor outcomes as-
sociated with AKI could simply be the consequence of selecting
a sicker patient population [6, 7]. There is currently no clear
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consensus to what extent the link between AKI and adverse
outcomes is one of correlation or causation. This review uses
the Bradford Hill criteria for causality as a framework to address
this question.
MATERIALS ANDMETHODS
A background literature review was performed using PubMed
(US National Library of Medicine) and the Web of Science
(Clarivate Analytics) databases to examine the relevant evi-
dence on the epidemiology of AKI in intensive care unit (ICU)
populations. Publications prior to 2004 were excluded, as no
standard diagnostic criteria for AKI existed before this date [8].
Publications included at each stage of the review are described
in the relevant sections.
The Bradford Hill criteria describe a number of general fea-
tures that characterize a causal relationship between an expo-
sure and an outcome [9]. The literature was examined and
applied to each criterion in turn to assess how far the associa-
tion between AKI and adverse outcomes meets the grounds for
causality. In order to assess the magnitude and specificity of the
association, we used a random effects model to estimate
weighted averages of the odds ratio (OR) or should read hazard
ratio (HR) from each study.
The Bradford Hill criteria specified for the relationship be-
tween AKI and mortality include the following:
RESULTS
Plausibility: are there accepted mechanisms by which
AKI could cause death?
Before considering the complications of AKI, it is important to
bear in mind the heterogeneity of the condition. In the critical
care setting, most AKI arises from renal injuries linked to is-
chaemia, inflammation or toxaemia from by a broad range of
aetiologies. Animal studies have observed drastically different
genetic transcription patterns in renal cells affected by AKI
caused by ischaemia–reperfusion compared with AKI caused by
extracellular fluid depletion [10, 11]. This points to variation in
the nature of AKI at a genetic, molecular and cellular level that
may reasonably be expected to be paralleled by varying clinical
phenotypes, limiting the scope of any general conclusions.
Fluid overload and direct physiological consequences of AKI.
The three physiological hallmarks of severe AKI include hyper-
kalaemia, metabolic acidosis and fluid overload. Together they
are suggested to account for between 33% and 70% of the excess
mortality attributed to AKI during critical illness [19].
Hyperkalaemia and metabolic acidosis occur when glomerular
and tubular mechanisms in the excretion of organic acids and
metabolites are severely compromised. These metabolic abnor-
malities are synergistic both in their kinetic and dynamic prop-
erties, increasing the risk of arrhythmias and reducing cardiac
contractility. While the use of such abnormalities can be readily
corrected through renal replacement therapy (RRT), such sup-
portive therapy only corrects the consequences of AKI, not the
underlying pathology.
A significantly reduced glomerular filtration rate in severe
AKI leads to oliguria or anuria and consequently to fluid over-
load. Pulmonary oedema is often reported as a cause of death in
AKI patients, and the SOAP study, among others, observed that
patients who died of AKI had significantly more positive fluid
balance than survivors [15–17, 20]. Positive fluid balance
remained an independent predictor of mortality even after cor-
recting for comorbidity and disease severity [17, 21]. However,
fluid accumulation is not only the result of AKI but also resusci-
tation or damage to other organ systems. In addition, fluid accu-
mulation can itself lead to or worsen AKI via interstitial
oedema, increased venous congestion and reduced renal blood
flow [22]. Therefore the relationship between AKI and fluid
overload is multidirectional.
RRT. Mortality in patients with the severest forms of AKI requir-
ing RRT is high. Although lifesaving for some patients, RRT does
not reverse the negative impact of AKI [23] and itself has been
shown to be an independent risk factor for mortality [24].
However, these observations are likely to be confounded, as
only the sickest patients receive RRT. A recent multicentre ran-
domized controlled trial investigating the optimum timing of
RRT in patients with severe AKI and sepsis showed that a
‘watch and wait’ approach resulted in less use of RRT and did
not increase mortality [25]. Observational findings have shown
that even in patients receiving RRT, there remains an indepen-
dent negative impact of positive fluid balance on patient out-
comes [26, 27]. Furthermore, although greater fluid overload is
associated with increased mortality, higher net ultrafiltration
rates to resolve fluid overload have also been correlated with
adverse outcomes, indicating that once fluid overload has oc-
curred in AKI, measures to rapidly resolve it with RRT may
themselves be harmful [28]. Overall, distilling the impact of RRT
on mortality is complex. The fact that RRT can manage electro-
lyte fluctuations, acid–base disturbance and fluid balance but
does not eliminate excess mortality suggests that other mecha-
nisms contribute to mortality in AKI.
Organ crosstalk and cardiovascular risk. AKI has been shown to
have widespread deleterious effects on the cardiovascular, re-
spiratory and neurological systems. This is an example of the
‘organ crosstalk’ concept, through which a kidney insult may
trigger changes in distant systems [29]. AKI results in increased
risk of acute lung injury, inflammation of the brain with disrup-
tion of the blood–brain barrier and cardiac impairment [30–32].
The mechanism by which signals are mediated between the
afflicted kidney and distant organ sites is likely to be multifacto-
rial, with cellular, molecular, immunological and epigenetic
components [29].
1. Plausibility: is there an accepted mechanism by which
AKI could cause death?
2. Temporality: is the time frame between AKI and death
consistent with the proposed mechanism?
3. Analogy: are there any similar exposure–outcome rela-
tionships that are comparable?
4. Magnitude: how large is the difference in mortality be-
tween AKI and non-AKI populations?
5. Specificity: does the association persist when other
possible explanatory factors are excluded?
6. Coherence and experiment: is the proposed mecha-
nism supported both by laboratory and experimental
evidence?
7. Biological gradient: does mortality increase with in-
creasing AKI severity?
8. Consistency: is the association reproducible across dif-
ferent patient populations?
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While CKD is a well-established risk factor for cardiovascular
disease [33, 34], less is known about the cardiovascular risk attrib-
utable to AKI. AKI has been found to worsen cardiovascular out-
comes in those with existing cardiac disease, resulting in
increased rates of heart failure and major adverse cardiac events
(MACEs) [35, 36]. Where de novo cardiac events are concerned, AKI
was observed to increase the risk of acute coronary events over
the medium to long term by 50%, but there is limited evidence
about the risk of MACE in the context of acute AKI [37–39].
Multiple mechanisms have been suggested for this associa-
tion. For patients who require RRT, the phenomenon of ‘myo-
cardial stunning’ may play a role. In a study of AKI treated with
intermittent haemodialysis, all patients developed new regional
wall motion abnormalities and reduced left ventricular contrac-
tility during dialysis with evidence of myocardial ischaemia
[40]. Mouse models have demonstrated apoptosis of cardiac
myocytes during AKI with simultaneous reduced cardiac output
[41]. The inflammatory state of AKI is also known to alter the
circulating cytokine profile, which is in turn hypothesized to di-
rectly damage cardiac myocytes [42, 58].
The link between AKI and cardiovascular risk is confounded
by high levels of comorbidity in AKI patients, known to have sig-
nificantly higher rates of pre-existing heart failure, hyperten-
sion and diabetes [23]. While this could account for some of the
outcomes observed, it cannot account for the real-time cardiac
impairment described in the preceding literature.
Susceptibility to infection. Critically ill patients with AKI have
been found to have approximately double the incidence of infec-
tion than those without AKI [43]. These infections are not trivial:
in one large study, patients with AKI requiring RRT were more
than twice as likely to develop severe sepsis [44]. This risk dimin-
ished with time but persisted even after resolution of the AKI [44].
The mechanism by which AKI increases the rate of infection
is likely multifactorial. First, as a systemic inflammatory state,
AKI may have a directly immunosuppressive effect through in-
creased concentrations of circulating cytokines as well as im-
paired cell-mediated immunity, acting through key molecular
mediators such as resistin [45–47]. Second, AKI is associated with
increased length of stay (LOS), both in hospital and the ICU, which
would be expected to increase the risk of infection [23, 48]. Even
small increases in serum creatinine have been found to cause a
statistically significant increase in LOS, and the magnitude of cre-
atinine increase correlates with LOS [49]. RRT is a further compli-
cating factor due to the presence of indwelling lines and devices
resulting in an increased risk of nosocomial infection [50].
Despite the increased prevalence of infection, the clinical
significance of the infection burden in AKI patients has been
called into question by Bernier-Jean et al. [43] and Hoste et al.
[50], both of whom observed no excess mortality attributable to
the increased rate of infection.
Temporality: is the time course of short-term mortality
consistent with hypothesized AKI pathophysiology?
The exact time frame used to define short-term mortality is
generally taken as the duration of hospital or ICU admission.
The mechanisms discussed above offer a plausible explanation
for mortality on this timescale. Hyperkalaemia, acidosis and
fluid overload are all acute complications with the capacity to
cause death within hours or days. Other mechanisms, including
systemic inflammation, infection, MACEs and organ crosstalk,
appear to act over a more varied timescale and persist after re-
covery from critical illness. This makes their relationship with
acute mortality more difficult to discern but does not necessar-
ily detract from their clinical significance during an AKI
episode.
Evidence is mounting that AKI is also a predisposing factor
for the development of CKD and ESKD, contradicting the histori-
cal view of AKI as a wholly reversible condition [5, 51]. While
tubules do have the capacity to regenerate following an initial
insult, allowing measured renal function to apparently return to
baseline, animal models reveal that the kidney often develops
tubulointerstitial fibrosis after AKI, resulting in chronically im-
paired renal function [13, 52]. Overall, the pathophysiology of
AKI is sufficiently heterogeneous to account for morbidity and
mortality on a wide range of timescales.
Analogy: comparison between AKI and acute respiratory
distress syndrome
Bradford Hill argued that the weight of evidence for a causal re-
lationship between an exposure and outcome may be increased
by an analogy to a similar exposure with a known causal associ-
ation to a similar outcome [53]. Acute respiratory distress syn-
drome (ARDS) provides a model of clinical syndrome arising
from an initial single-organ insult that results in distant organ
damage and dysfunction, with an associated increase in mortal-
ity, much like AKI.
There are a number of similarities in the nature of the two
diseases: the cause of AKI is often multifactorial and similarly
ARDS has a range of causes, both pulmonary and extrapulmo-
nary [54]. The subsequent impact on lung function often results
in patients requiring mechanical ventilation as a supportive
measure. The lack of any specific interventional treatments for
ARDS reflects the complexity of the underlying pathophysiol-
ogy, a problem also encountered in AKI. As more is discovered
about both ARDS and AKI, researchers are uncovering distinct
subtypes of each syndrome, each with unique characteristics
and potentially distinct treatment targets [14, 55].
The diagnosis of ARDS, like AKI, is associated with worse
short- and long-term outcomes. Short-term mortality has been
found to vary widely between epidemiological studies, from
15% to 72%, and has decreased over time [56]. ICU-specific mor-
tality has been estimated at 38% [57]. However, cause of death is
most often ascribed either to the cause of or complications of
ARDS rather than the lung injury itself [58]. Therefore, like AKI,
there is no clear consensus on the degree to which ARDS di-
rectly causes mortality. This is likely to reflect the pathophysiol-
ogy of multiorgan failure, where several organ injuries,
including AKI and ARDS, combine to mediate the risk of death.
The impact on long-term morbidity has also been prospec-
tively characterized for ARDS survivors, demonstrating signifi-
cantly poorer overall health than predicted, up to 5 years after
discharge from ICU [59]. The results of prospective studies are
still pending for AKI in the ICU, but there is a large body of retro-
spective evidence linking AKI with worse longer-term outcomes
[60]. The current lack of understanding of the pathophysiology
of both ARDS and AKI limits further comparison, and a deeper
understanding of the model of organ crosstalk is required to
fully assess their similarities and differences.
Magnitude and specificity: how strong is the association
between AKI and short-term mortality?
Table 1 compares studies examining short-term mortality for criti-
cally ill patients with and without AKI. Acute mortality was consis-
tently higher in AKI patients (13.3–58.0%) than in those without
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AKI (5.5–28.0%). It should be noted that the diagnostic criteria vary,
but all studies used the closely related Risk, Injury, Failure, Loss,
End-stage kidney disease (RIFLE), Acute Kidney Injury Network
(AKIN) or Kidney Disease: Improving Global Outcomes (KDIGO)
classifications [61, 62]. The incidence of AKI, defined as any AKI di-
agnosed during ICU admission, showed marked variability, ranging
from 25.5% to 67.2%. This is consistent with other sources that
reported rates between 5.7% and 67.2% [63].
However, these crude data alone are insufficient to quantify
the magnitude of the association between AKI and the risk of
death. As these are mostly retrospective cohort studies, the ex-
posed (AKI) and unexposed (no AKI) populations were not
matched at the time of candidate selection, introducing the possi-
bility of confounding. In order to evaluate the specific impact of
AKI on mortality and its statistical significance, this bias can be
decreased by statistical correction for known confounders. Two
main statistical methods have been used in the literature for this
purpose: Cox proportional hazards regression analysis of time to
event data and multivariate logistic regression analysis of sur-
vival at a specific time point. Variables adjusted for in observa-
tional AKI studies commonly include age, gender, comorbidity
and critical illness severity scoring. These analyses provide ad-
justed ORs/HRs that can be compared between studies.
Using these metrics, the studies in Table 1 reported a relative
increase in short-term risk of death (ORs or HRs) of between
1.08 and 5.96. The adjusted OR/HR is presented as a forest plot
in Figure 1. These magnitudes were all statistically significant
after adjusting for confounders (P 0.003 for all studies), al-
though reported confidence intervals were generally broad.
These magnitudes are also highly clinically significant, al-
though the variation in magnitude is striking.
Using a random effects model, we combined these results to
calculate the weighted mean. This model estimated a 2.3-fold
increase in the risk of death attributable to AKI, which was sta-
tistically significant. Even the lower bound on this estimate sug-
gests a 30% increased risk of death, a highly important clinical
finding for such a common condition.
It is relevant at this stage to consider the interaction be-
tween AKI and illness severity. As stated at the outset, many
see the relationship between AKI and adverse outcomes as a
corollary of the correlation between AKI and illness severity.
Many of the included studies explored this relationship. Where
the relevant analysis was included, authors consistently ob-
served that AKI was associated with higher illness severity, as
quantified by scores such as the Acute Physiology and Chronic
Health Evaluation (APACHE) or the Simplified Acute Physiology
Score (SAPS) II [2, 68, 69]. However, after multivariate analysis to
correct for this, the relationship between AKI and mortality per-
sisted and was consistently greater than the association be-
tween illness severity and mortality. Barrantes et al. [2] used a
modified version of the APACHE to remove the contribution of
renal function to the APACHE score. After multivariate logistic
regression, AKI was again significantly associated with mortal-
ity, but the modified APACHE score was not. These findings con-
firm that the relationship between AKI and mortality is not
explained by illness severity alone and support the case for an
intrinsic link between AKI and adverse outcomes.
There are limitations to this evidence. Only a small number
of studies have reported adjusted models for the association be-
tween AKI and risk of death in the ICU, with relatively modest
sample sizes. In addition, there was significant heterogeneity
between study designs, with differing analyses and survival
time frames. Despite these limitations, the weight of evidence
suggests that after correcting for confounding factors, AKI is
strongly associated with a large, clinically important and statis-
tically significant increase in mortality.
Experiment and coherence: is the relationship between
AKI and adverse outcomes supported by experimental
evidence?
Two main types of research provide the bulk of the evidence for
assessing outcomes of AKI. First is epidemiological data arising
primarily from retrospective cohort studies [65]. These may be
weakened by selection bias, limited clinical detail and con-
founding due to the absence of a matched control group, mak-
ing it more difficult to infer causality. Second, insights into the
pathophysiology and complications of AKI are based almost ex-
clusively on animal models, which provide limited comparisons
to the human system.
Earlier in this review, mechanisms were discussed by which
AKI may increase mortality, namely metabolic disturbance,
fluid overload, organ crosstalk, cardiovascular risk and suscepti-
bility to infection. If these truly mediate the link between AKI
and death, then counteracting their effect should lead to a re-
duction in mortality.
To test the impact of reducing fluid overload in AKI, the
Conservative vs. Liberal Approach to Fluid Therapy of Septic
Shock in Intensive Care trial randomized patients with septic
shock to receive fluid according to either standard guidelines or
a restrictive fluid management protocol [71]. In the latter group,
AKI was significantly less likely to worsen, and mortality was
lower, although the trial was not powered to identify significant
mortality differences between the groups. Multicentre studies
are under way to verify these preliminary findings. Conversely,













OR/HR (95% CI)a P-value*
Hoste et al. [64] ICU 5383 67.2 5.5 13.3 – –
Mandelbaum et al. [3] ICU 14 524 57.0 6.7 16.0 – –
Nisula et al. [65] ICU 2907 39.3 10.2 25.6 – –
Barrantes et al. [2] ICU 471 25.5 16.4 45.8 3.7 (2.2–6.1) –
Harris et al. [66] Surgical ICU 624 47.0 4.0 19.0 1.08 (1.03–1.14) 0.003
Masewu et al. [67] ICU 476 52.7 28.0 58.0 1.82 (1.34–2.48) <0.001
Reddy et al. [68] ICU 250 45.9 3.1 23.4 5.96 (1.9–18.6) <0.002
Ralib and Nor [69] ICU 143 65.0 10.0 30.1 2.61 (1.06–6.42) 0.001
CI, confidence interval. aAdjusted HR denoted by bold values.
*P-values refer to the adjusted OR/HR.
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in the elective perioperative setting, conservative fluid manage-
ment aimed at preventing fluid overload has been associated
with increased risk of post-operative AKI, illustrating the com-
plexity of the relationship between fluid status and AKI [72]. As
discussed in the ‘Plausibility: are there accepted mechanisms
by which AKI could cause death?’ section, in patients with the
severest form of AKI requiring RRT, observational studies have
suggested a harmful effect of fluid overload [16, 26–28, 73].
To probe the effect of cardiovascular risk reduction after AKI,
investigators have explored the effect of statins on patient out-
comes. Wu et al.’s [74] large cohort study of dialysis-requiring
AKI patients observed that statin use was associated with sig-
nificantly reduced mortality both during hospital admission
and at the 1-year follow-up. In a population with AKI-on-CKD,
statin use after AKI was associated with a significant reduction
in mortality and readmission [75]. Surprisingly, the authors did
not observe a significant reduction in the rate of cardiovascular
events in the same time period, pointing to an alternative
mechanism of mortality benefit [75].
Biological gradient: do adverse outcomes increase with
increasing AKI severity?
A biological gradient is a relationship between the severity of an
exposure and the magnitude of its outcome, akin to a pharma-
cological ‘dose–response’ phenomenon. This is convenient to
study in AKI, as the diagnostic criteria include staged measures
of severity.
Short-term mortality increases with increasing severity of AKI.
Data from several studies describing short-term mortality strat-
ified by AKI severity are demonstrated in Table 2 and Figure 2.
As in Figure 1, studies have been included that corrected for
confounding factors and therefore express mortality as adjusted
ORs. Again, a random effects model has been used to calculate
the weighted mean for mortality at each stage of AKI.
Unlike those studies examining adjusted risk of hospital
mortality in AKI (Figure 1), studies examining AKI severity had
larger sample sizes (1032–325 395) and a number were prospec-
tive. The pooled data clearly demonstrate an increase in mortal-
ity, with adjusted ORs of 1.5, 2.4 and 4.1 for Stages 1–3,
respectively, although the confidence intervals do overlap be-
tween stages. The pooled data were weighted heavily by Thakar
et al. [76], in a large study consisting of >300 000 patients. If this
study is excluded, then mortality is still seen to increase with
each stage of AKI, albeit with smaller ORs of 1.2, 1.7 and 2.9 for
Stages 1–3, respectively.
Despite the biological gradient, there are exceptions. A possi-
ble explanation for the different trends seen between studies is
that the definition of AKI Stage 2 is narrow, incorporating a rela-
tively small range of serum creatinine values, making it more
susceptible to outliers [3]. In addition, higher stages of AKI may
have competing endpoints with mortality, such that a patient
who dies with low-stage AKI is unable to progress to a higher
stage. This may result in underestimation of the mortality asso-
ciated with higher stages of AKI unless competing risks are con-
sidered in the analysis [77]. In one study, while the biological
gradient is present, only severe (Stage 3) AKI was significantly
associated with mortality [78]. This may suggest that while se-
vere AKI is causative of mortality, less severe AKI is merely as-
sociated with the risk of death.
Overall, these data support the existence of the biological
gradient between AKI severity and mortality with some variabil-
ity that may be implicit in the AKI definition.
The presence of a biological gradient arising from the epide-
miological data suggests that early diagnosis of AKI and preven-
tion of progression should improve outcomes. Much research is
under way to explore the role of urinary biomarkers in the early
diagnosis of AKI, with promising results [79, 80]. Electronic alert
systems are in use with the aim of expediting AKI detection and
treatment, but such systems (including the Streams application;
DeepMind Technology, London, UK [81]) have thus far failed to
demonstrate significant improvements in clinical outcomes [82,
83]. A related software system was able to predict more than
half of all AKI episodes and >90% of severe AKI requiring dialy-
sis, although with a high false-positive rate [84]. AKI care bun-
dles offer more promise. In two separate studies, Kolhe et al. [85,
86] observed that patients who had an AKI care bundle com-
pleted within 24 h of diagnosis had significantly reduced risk of
death and progression of AKI. Further work is required to estab-
lish whether the improved outcomes result from preventing
AKI progression or preventing physiological complications.
Consistency: is the association between AKI and
mortality reproducible in different populations?
AKI has been found to be an independent risk factor for mor-
tality among diverse patient groups, including general hospi-
tal inpatients, medical patients and surgical patients
undergoing lung transplant, liver transplant and general or
cardiothoracic surgery [49, 88–93]. Another measure of consis-
tency is uniformity across a range of age groups, including the
extremes of age. AKI independently increased mortality and
LOS in paediatric ICU patients and children undergoing
Study
Random effects model










































FIGURE 1: Short-term mortality in patients with AKI, relative to those without, adjusted for confounders. Factors adjusted for include the following. Barrantes et al. [2]:
not specified—selected from univariate analysis; Harris et al. [66]: ethnicity, CKD, APACHE score, sepsis, mechanical ventilation, liver failure; Masewu et al. [67]:
organ systems affected, oxygen saturations, tachypnoea; Reddy et al. [68]: age, APACHE score, admission creatinine, sepsis, RRT; Ralib and Nor [69]: age and Sequential
Organ Failure Assessment score.
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cardiac surgery [94–97]. Among the elderly population, only
limited data are available, as most studies remove the effect of
age as a potential confounder. From the few studies that do re-
port data on the geriatric population, short-term mortality
appears to be higher in those with AKI [99]. However, at least
one study found no difference in outcome between the ‘risk’
and ‘injury’ groups when RIFLE criteria were used [98, 99]. This
suggests that either the effect on mortality in this population
is smaller or that the diagnostic criteria are less valid, possibly
due to the physiological changes of ageing and increased bur-
den of comorbidities. In our entire literature search, we did
not identify any studies that reported no association between
AKI and mortality.
DISCUSSION
Starting from the well-established finding that AKI is crudely
associated with increased mortality, we applied the Bradford
Hill criteria to test the strength of evidence and determine
whether this association is causal.
AKI has a complex and heterogeneous pathophysiology with
the potential to cause multiple systemic complications. The dis-
ease processes implicated in AKI provide plausible mechanisms
by which it could directly increase short-term mortality, notably
metabolic disturbance, fluid overload, infection risk and distant
organ impairment. AKI was compared with the analogous sys-
tem of ARDS, which provides a precedent for single-organ
Study
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Heterogeneity: I2 = 99%, τ2 = 0.2802, P < 0.01
Heterogeneity: I2 = 99%, τ2 = 0.7981, P < 0.01

























































































FIGURE 2: Forest plot demonstrating the relationship between AKI stage and short-term mortality. Stages 1–3 equate to AKIN/KDIGO 1, 2, 3 and RIFLE, respectively. ORs
relate to comparison between the relevant stage of AKI and no-AKI after adjusting for confounders. Factors adjusted for include the following: Mandelbaum et al. [3]:
age, non-renal SOFA score, comorbidity; Thakar et al. [76]: age, comorbidity, admission diagnosis, source of admission, 11 laboratory test results; Clec’h et al. [77]: non-
renal SOFA score, McCabe class, admission source, organ failure; Hoste et al. [23]: admission source, serum creatinine on admission to ICU and non-specified ‘fixed pre-
dictors’; Ostermann et al. [78]: age, SOFA score, number of organ failures, gender, chronic illness, mechanical ventilation, AKI categories, RRT and anaemia. SOFA,
Sequential Organ Failure Assessment.
Table 2. Short-term mortality in patients with AKI stratified according to AKI severity
Study
Patient
group Severity score Cohort size
Adjusted OR for mortality (95% CI)a
Stage 1 Stage 2 Stage 3
Mandelbaum et al. [3] ICU AKIN 14 524 1.38 (1.2–1.59) 1.26 (1.05–1.50) 2.5 (1.98–3.12)
Thakar et al. [76] ICU Non-standard 325 359 2.23 (2.17–2.30) 6.08 (5.74–6.44) 8.60 (8.07–9.15)
Clec’h et al. [77] ICU RIFLE 8639 1.58 (1.32–1.88) 3.99 (3.43–4.65) 4.12 (3.55–4.79)
Hoste et al. [23] ICU KDIGO 1802 2.09 (1.19–3.67) 2.64 (1.33–5.22) 5.63 (3.43–9.22)
Ostermann et al. [78] ICU RIFLE 22 303 0.82 (0.73–0.91) 1.05 (0.87–1.27) 2.27 (1.92–2.69)
Weighted mean – – – 2.09 5.53 7.87
aStages 1–3 equate to AKIN/KDIGO 1, 2, 3 and RIFLE, respectively.
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dysfunction causing multisystem complications and adverse
outcomes. Reviewing the epidemiological data in more detail, it
was found that after correction for confounding factors, AKI
specifically increases mortality with a magnitude that is both
clinically and statistically significant. By grouping AKI patients
according to severity (Stages 1–3), a biological gradient emerges
from the data with mortality increasing with disease severity.
The association has been consistently demonstrated across a
broad spectrum of patient types, disease groups and age ranges.
There are a number of limitations to this review. Despite the
quantitative treatment of certain aspects of the discussion, this
is neither a systematic review nor a meta-analysis and our cov-
erage of the literature is incomplete. Second, the Bradford Hill
criteria, although well established, are just one of the many em-
pirical approaches to establishing causality. The criteria were
originally applied to the association between occupational or
environmental exposures and disease, rather than disease and
mortality as in this setting. Finally, the long-term complications
of AKI, including mortality, CKD, ESKD and cardiovascular dis-
ease, which are of great clinical significance, have not been dis-
cussed in detail.
Based on our findings, it seems extremely likely that AKI is a
direct contributing factor to mortality in the proportion of
patients, but the heterogeneity of the condition and the variabil-
ity of its causes and consequences mean that this conclusion
cannot be drawn definitively for all.
Future work should focus on the prevention and mitigation
of the complications of AKI that contribute to mortality. Areas
of study should include practical interventions to reduce LOS,
molecular treatments targeting the immunosuppressive and or-
gan crosstalk pathways implicated in AKI, quantification and
reduction of acute risk of MACEs during AKI, cardiovascular risk
reduction after AKI and optimization of fluid balance through
RRT, conservative and medical strategies.
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